Safety and Efficacy of Oral Versus Intravenous Amiodarone in the Treatment of AF
Status:
Unknown status
Trial end date:
2015-05-01
Target enrollment:
Participant gender:
Summary
Atrial fibrillation (AF) remains a significant contributor to cardiovascular morbidity.
Amiodarone is a potent antiarrhythmic drug; however, patients receiving IV amiodarone are at
high risk for phlebitis. Phlebitis may lead to infection, additional medical intervention,
delay in treatment, and prolonged hospitalization. Therefore, examining new therapy approach,
aimed to reduce the incidence of phlebitis is a valuable clinical and research goal.
Aim: To evaluate the safety and efficacy of oral versus intravenous (IV) Amiodarone in the
treatment of AF of recent onset (duration < 48 h).